CyndRx focuses on medical technology projects achievable within a 1-4 year timeline. Our goal is to develop innovative and disruptive technologies leveraging our in-house industry experiences and expertise to provide high-value return of investment. Currently, CyndRx is fully dedicated to the development and commercialization of a market-differentiating vascular closure device platform, AbsorbaSeal™. AbsorbaSeal™ , a Vascular Closure Device (VCD) platform, virtually eliminates the learning curve of VCDs with its very easy-to-use delivery and deployment, achieves safe and effective hemostasis with a bioabsorbable sealing mechanism that allows the target vessel to heal without chronic implants, while also focusing on economic value. The AbsorbaSeal™ VCD platform is scalable from small through large bore access (5F to 24F), offering the most innovative, clinically and economically valuable VCD platform to date.